Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warning letters

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplements purporting to cure diseases ranging from Alzheimer's to bird flu are the topic of three warning letters sent by FDA in January. In the letters, FDA addresses claims for Long Life Catalog Company's supplement Zap-V, Robert Davis' All-Natural Interferon and Trim International's TCR Cell Rejuvenator. Specifically, FDA takes issue with Zap-V's claims that the product reduces inflammation and acts as an "anticancer, anti-tumor, antiviral" medication, according to the Jan. 30 letter. In Jan. 24 correspondence, the agency targets claims made to promote All-Natural Interferon as "an immune system booster." Finally, in a Jan. 9 letter, the agency addresses claims that TCR Cell Rejuvenator "helps prevent recurrent herpes, common cold and flu, and is used to treat patients with Alzheimer's, Parkinson's, cancer and other infectious diseases and neurological disorders." All the claims are found on the individual products' web sites, according to FDA...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS099141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel